Monopteros
0 followers
‌
Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset MPT-0118, is conducting a phase 1 clinical trial to investigate reprogramming regulatory T cells in solid tumors.
Industries
Headquarters
Employees
Links
Org chart
Peter Keller
Chief Executive Officer
Peter Keller
Collapse
Arthur DeCillis
Chief Medical Officer
Jon Lawson
Manufacturing
Norma Kim Ascroft
Regulatory Affairs
Sami Karaborni
Drug Development
Vijayapal Reddy
Non-Clinical Safety
Yun Gao
Chemistry
